The funding will support a collaboration between ProtonDx and Imperial College London to evaluate a host gene expression test on a next-gen test system.
The company is developing a noninvasive urine-based test for sexually transmitted infections including chlamydia and gonorrhea.
NEW YORK – After rising 9 percent in October, the 360Dx Top 30 continued its upward momentum last month, rising an additional 9 percent in November. The 360Dx Top 30 outpaced the broader markets as ...
The PCR-based point-of-care test runs on the Cobas Liat platform and returns results for three Bordetella species in 15 minutes.
NEW YORK – Precision oncology firm Cleveland Diagnostics announced Monday that its IsoPSA test for prostate cancer has received approval from the US Food and Drug Administration. The blood-based test ...
The company's Check4 electrochemical detection platform can detect nucleic acid targets from blood or saliva samples in less than five minutes.
The analyzer integrates clinical chemistries, immunoassays, and hematology assays into a single plug-and-play instrument.
NEW YORK – What were the articles that gained the most interest from 360Dx readers last week? Here are the top five: ...
Abbott CEO Robert Ford called cancer testing a "critically important market" that the firm has made a priority to move into.
The US Food and Drug Administration granted clearances for PCR-based infectious disease tests from multiple companies as well as other in vitro diagnostic tests.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback